NRSN and H1Z Related Headlines
Go Back- NeuroSense receives South Korean patent for ALS drug PrimeC
- NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
- NeuroSense receives Japanese patent for ALS drug candidate PrimeC
- NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
- NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
- NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
- NeuroSense reschedules Health Canada meeting to include additional data
- NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
- PrimeC New Data to Be Presented at AD/PD™ 2026 Conference
- NeuroSense's ALS drug shows slower disease progression in published study
- JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
- PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
- NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
- NeuroSense receives US patent for Alzheimer's treatment through 2043
- NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
- World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
- NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
- NeuroSense to Host Investor Webinar on December 8, 2025
- NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
- NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
- NeuroSense raises $500,000 in private placement at 40% premium
- NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
- NeuroSense Provides Business Update and Progress for the First Half of 2025
- Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community
NRSN and H1Z Related Press Releases
Go Back- NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
- NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
- NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
- NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
- NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
- PrimeC New Data to Be Presented at AD/PD™ 2026 Conference
- JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
- PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
- NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
- NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
- World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
- NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
- NeuroSense to Host Investor Webinar on December 8, 2025
- NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
- NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
- NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
- NeuroSense Provides Business Update and Progress for the First Half of 2025
- Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community
